Antiproliferative effect of gold(I) compound auranofin through inhibition of STAT3 and telomerase activity in MDA-MB 231 human breast cancer cells

Nam-Hoon Kim*,†, Hyo Jung Park‡, Mi-Kyung Oh & In-Sook Kim*

Department of Medical Life science, College of Medicine, The Catholic University of Korea, Seoul 137-710, Korea

INTRODUCTION

Metal-containing compounds possess a wide spectrum of biological functions and have attracted interest because of their applications in medicinal chemistry (1, 2). For example, the platinum compound cisplatin is a well-known anticancer drug, and gold compounds including auranofin have long been used to treat rheumatoid arthritis (1, 3, 4).

Signal transducer and activator of transcription 3 (STAT3) and telomerase are considered attractive targets for anticancer therapy. The in vitro anticancer activity of the gold(I) compound auranofin was investigated using MDA-MB 231 human breast cancer cells, in which STAT3 is constitutively active. In cell culture, auranofin inhibited growth in a dose-dependent manner, and N-acetyl-L-cysteine (NAC), a scavenger of reactive oxygen species (ROS), markedly blocked the effect of auranofin. Incorporation of 5-bromo-2’-deoxyuridine into DNA and anchorage-independent cell growth on soft agar were decreased by auranofin treatment. STAT3 phosphorylation and telomerase activity were also attenuated in cells exposed to auranofin, but NAC pretreatment restored STAT3 phosphorylation and telomerase activity in these cells. These findings indicate that auranofin exerts antitumor effects in MDA-MB 231 cells and its activity involves inhibition of STAT3 and telomerase. Thus, auranofin shows potential as a novel anticancer drug that targets STAT3 and telomerase. [BMB Reports 2013; 46(1): 59-64]

Auranofin [2, 3, 4, 6-tetra-O-acetyl-1-thio-β-D-glucopyranosato-S-(triethylphosphine)gold(I)] is a gold(I)-based drug. The compound reacts with thiol and selenol groups; therefore, proteins that contain reactive cysteine and selenocysteine in their active sites are targets of auranofin (5, 6). The selenocysteine-containing thioredoxin reductase (TrxR) is a specific target of this compound (7). TrxR catalyzes the NADPH-dependent reduction of oxidized thioredoxin (Trx), which contributes to intracellular redox regulation, antioxidant defense, apoptosis inhibition, and cell proliferation (8, 9). Elevated levels of Trx and TrxR have been detected in several cancer cells, and high Trx/TrxR plays a role in cell proliferation and resistance to chemotherapy. Therefore, the Trx/TrxR system has been targeted in cancer therapy (10, 11). Auranofin is a potent TrxR inhibitor that induces mitochondrial permeability transition, cytochrome c release, reactive oxygen species (ROS) generation, and apoptotic cell death (12, 13). Based on its ability to inhibit TrxR and stimulate ROS production, auranofin has shown promise as an anticancer agent in cancer cell lines including human leukemia, ovarian cancer, cervical cancer, lung cancer, and breast cancer (13-18). However, the precise mechanisms underlying its effects on cell growth and targeted proteins are still largely unknown.

Signal transducers and activator of transcription 3 (STAT3) is a transcription factor that mediates cell growth and differentiation, and contributes to tumorigenesis by promoting cell proliferation and angiogenesis (19, 20). Constitutively active STAT3 is frequently detected in human cancer cell lines and metastatic malignant tumor including breast cancer (21, 22). Recent study demonstrated that STAT3 also regulates the expression of telomerase reverse transcriptase (23), which maintains telomere length during DNA replication and is needed for tumor cell survival. Accordingly, STAT3 is an attractive target for anticancer therapy in cancers with elevated STAT3 activity (24).

In a previous study, we reported that the anticancer effects of auranofin in acute promyelocytic leukemia cell lines were mediated by ROS production and p38 mitogen-activated protein kinase activation (14, 15). The ability of auranofin to inhibit IL-6-induced activation of STAT3 was also demonstrated in HepG2 human hepatoma cells (25). Nakaya et al. reported that auranofin induced apoptosis in human multiple myeloma cells by down-regulating STAT3 and inhibiting nuclear factor-kappa B activity...
Anticancer activity of auranofin via STAT3 inhibition
Nam-Hoon Kim, et al.

Anticancer activity of auranofin via STAT3 inhibition (26). In addition, intracellular ROS can regulate STAT3 and telomerase activity (27). These findings raise the possibility of a potent anticancer function of auranofin via ROS-dependent STAT3 and telomerase inhibition in cancer cells that require high STAT3 and telomerase activity for cell survival and antiapoptosis.

It is not clear whether auranofin inhibits cell growth and the activity of STAT3 and telomerase in breast cancer cells in a ROS-dependent manner. Therefore, in the present study, we investigated the effects of auranofin on STAT3 and telomerase and its in vitro tumorigenic potential using MDA-MB 231 human breast cancer cells, in which constitutively active STAT3 is implicated in cell proliferation and survival.

RESULTS AND DISCUSSION

Antiproliferative effects of auranofin in MDA-MB 231 cells

To investigate the effect of auranofin on the growth of MDA-MB 231 cells, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay was performed to evaluate cell growth after 12-72 h treatment with various concentrations of auranofin. At doses up to 2 μM, auranofin dose-dependently decreased growth. This effect was inhibited by a 30 min preincubation with 10 mM N-acetyl-L-cysteine (NAC), which is a well known scavenger of ROS (Fig. 1A, B). It suggests ROS participation in the auranofin-mediated growth inhibition. Although our previous study showed that 2 μM auranofin blocked IL-6-induced STAT3 activation in HepG2 hepatoma cells, 2 μM auranofin was cytotoxic to MDA-MB 231 cells (Fig. 1A). Therefore, in the following experiments, 0.5 or 1 μM auranofin was used.

To examine the effect of auranofin on cell proliferation, the 5-bromo-2'-deoxyuridine (BrdU) incorporation assay was performed. As shown in Fig. 2, lower levels of incorporated BrdU were detected in the nuclei of auranofin-treated cells than in untreated control cells. These results indicate that auranofin inhibits cell proliferation and reduces in vitro growth of MDA-MB 231 cells.

Inhibition of anchorage-independent growth by auranofin

Tumorigenicity is correlated with anchorage-independent cell growth. To investigate the effect of auranofin on the tumorigenic potential of MDA-MB 231 cells, the soft agar colony formation assay was performed. As shown in Fig. 3, auranofin markedly reduced the number of colonies in soft agar. After 24 h, the number of colonies was 38 ± 2.5% (0.5 μM auranofin) and 23 ± 3.2% (1 μM auranofin) that of the untreated control. After 48 h, the number of colonies was 35 ± 18% (0.5 μM auranofin) and 11 ± 3.2% (1 μM auranofin) that of the untreated control. These findings indicate that auranofin reduces the in vitro tumorigenicity of MDA-MB 231 cells.

Downregulation of STAT3 phosphorylation and telomerase activity by auranofin

To explore whether the antiproliferative action of auranofin is associated with STAT3 regulation, we investigated the effects of auranofin on STAT3 phosphorylation and telomerase activity. Treatment with 1 μM auranofin for 3-12 h markedly blocked STAT3 phosphorylation (Fig. 4A, B), and STAT3 phosphorylation was restored by preincubation with 10 mM NAC for 30 min before auranofin treatment (Fig. 4C). Our data suggest that auranofin inactivates STAT3 through ROS-dependent mechanism. However, it could not be excluded that auranofin may interact
directly with reactive cysteine-bearing kinases or phosphatases which participate in STAT3 regulation. Then, thiol-containing NAC might interrupt the interaction and prevent the action of auranofin on STAT3 inhibition.

Cellular telomerase activity was determined using the TRAPeze telomerase detection kit, which is based on polymerase chain reaction (PCR) amplification of telomeric repeats. Untreated actively growing cells produced obvious telomerase products, showing the same pattern as the positive control (telomerase-positive cell extract), whereas the negative control using heat-inactivated telomerase did not show these products. Cells exposed to 1 μM auranofin exhibited weaker telomerase activity compared to controls.

Fig. 2. The inhibitory effect of auranofin on MDA-MB 231 cell proliferation. Cells were treated with auranofin (0.5 or 1 μM) and incubated for 24 or 48 h. BrdU (10 μM) was added to each culture 30 min before the end of incubation. To detect BrdU incorporation into DNA, immunocytochemistry was carried out using anti-BrdU antibodies and Alexa Fluor 488-conjugated secondary antibodies as described in Materials and Methods. DAPI staining was performed simultaneously. The stained cells were observed using a fluorescence microscope and photographed (×200). Experiments were performed twice with similar results, and representative results are shown.

Fig. 3. Inhibition of anchorage-independent growth of MDA-MB 231 cells by auranofin. Cells were treated with auranofin (0.5 or 1 μM) for 24 or 48 h. After harvesting cells and suspending them in culture medium containing 0.3% soft agar, the cells were plated over a 0.6% bottom agar layer. The cells were cultured for 14 days, and the 1 ml culture medium covering the top agar layer was changed every 3 days. (A) Colonies that formed in the soft agar were stained with 1 mg/ml MTT. (B) Colonies in three random fields of each well were counted and expressed as a ratio to the untreated control cells. Results are expressed as mean ± SD of three separate experiments. **P < 0.005, ***P < 0.0005 versus untreated control.
Anticancer activity of auranofin via STAT3 inhibition
Nam-Hoon Kim, et al.

Fig. 4. Inhibition of STAT3 and telomerase activity in auranofin-treated MDA-MB 231 cells. Cells were treated with 1 μM auranofin for the indicated times (A) or treated for 12 h with increasing auranofin concentrations (0.3, 0.5, or 1 μM) (B). (C) Cells were preincubated with 10 mM NAC for 30 min before auranofin treatment (1 μM) for 5 h. Using cell lysates, STAT3 and tyrosine-phosphorylated STAT3 (PY-STAT3) were detected by Western blot analysis. (D) Cells were preincubated for 30 min in the absence or presence of 10 mM NAC and then exposed to 1 μM auranofin for 12 or 24 h. Telomerase activity was determined using the TRAPeze telomerase detection kit as described in Materials and Methods. Positive and negative controls were the cell extract from telomerase-positive cells supplied in the kit and heat-inactivated (85°C for 10 min) positive cell extract, respectively. All experiments were carried out three times with similar results.

activity; however, telomerase activity was restored by NAC pretreatment (Fig. 4D). Although, auranofin only partially inhibited telomerase activity, the compound completely inhibited STAT3 phosphorylation (Fig. 4A, D). These results suggest that MDA-MB 231 cells may also possess a STAT3-independent pathway that regulates telomerase reverse transcriptase.

The telomerase assay includes an additional primer/template to amplify an internal control in each reaction sample. Because amplification of the telomerase products and the internal control are semi-competitive, samples with high telomerase activity (e.g., positive control and untreated samples) produce less of the internal control. PCR-amplified telomerase products generally appear as a ladder with 6-bp increments, but in our experiments the telomerase products appeared as a broad diffuse smear (Fig. 4D). This result may have been caused by poor electrophoretic separation of the PCR products.

Our results indicate that auranofin inhibited cell growth, in vitro tumorigenicity, and the activity of STAT3 and telomerase. Because ROS scavenger NAC blocked the inhibitory ability of this compound, it is thought that auranofin-elevated oxidative stress inactivates STAT3 and attenuates telomerase activity, thereby inhibiting cell proliferation. Recently, Watson et al. showed that TrxR knockdown by siRNA transfection in HeLa cells did not induce ROS generation, even though TrxR activity was completely inhibited (28). Therefore, it is not clear whether ROS-related STAT3 inhibition is linked to the auranofin-reduced TrxR activity. Further study is required to investigate the relationship between auranofin-regulated STAT3 inhibition and decreased TrxR activity and ROS production in MDA-MB 231 cells.

In summary, auranofin exerts an antitumorigenic effect on MDA-MB 231 human breast cancer cells, and this effect is related to the inhibition of STAT3 and telomerase. Our findings suggest the potential of auranofin as a novel anticancer drug that targets STAT3 and telomerase, which are required for proliferation and tumorigenesis in several cancers, including breast cancer. We used MDA-MB 231 cells in this study because they express constitutively active STAT3 and are sensitive to auranofin. However, to confirm our findings, further study is needed using other breast cancer cells that express high levels of active STAT3 for survival and tumor development.

MATERIALS AND METHODS

Cell culture and treatment
MDA-MB 231 breast cancer cells, purchased from the American Type Culture Collection (Rockville, MD), were maintained in RPMI 1640 medium (Gibco Life Technology, Gaithersburg, MD) supplemented with 10% heat-inactivated fetal bovine serum (Gibco) at 37°C in 5% CO2. To investigate the effect of auranofin, cells were treated with 0.3-2 μM auranofin (Alexis, Lausen, Switzerland) for the indicated times.

Cell viability was determined by MTT assay. After culturing cells in the absence or presence of auranofin, 10 μM MTT (Sigma, Louis, MO) was added, and the cells were incubated for an additional 3 h. The cells were lysed by adding 100 μl isopropanol containing 0.04 M HCl solution. After 10 min, 100 μl
distilled water was added and the dissolved blue formazan was detected by measuring absorbance at 570 nm.

**BrdU incorporation assay**

Cell proliferation was evaluated by detecting BrdU incorporation into cellular DNA. MDA-MB 231 cells were seeded on glass slides and grown overnight. The next day, 0.5-1 μM auranofin was added to the cells, which were then cultured for an additional 24-48 h. For BrdU incorporation, 10 μM BrdU (Sigma, St Louis, MO) was added to the cell culture 30 min before the end of incubation. The cells were fixed with 4% paraformaldehyde for 20 min and then treated with 1 N HCl, followed by 0.1 M boric acid. After blocking with 10% normal donkey serum for 20 min and then treated with 1 N HCl, followed by 0.1 M of incubation. The cells were fixed with 4% paraformaldehyde Louis, MO) was added to the cell culture 30 min before the end of incubation. The cells were incubated with anti-BrdU antibodies and then washed with phosphate-buffered saline (PBS) three times, and then stained with Alexa Fluor 488-conjugated secondary antibody (Abcam, Cambridge, MA) for 2 h. The stained cells were observed and photographed using a fluorescence microscope (Axiovert 200, Zeiss, Germany).

** Colony formation assay**

A 0.6% soft agar solution was poured into a 12-well plate and solidified at room temperature. Onto the bottom layer, 0.3% top agar containing MDA-MB 231 cells (1 × 10⁵ cells) was poured. An extra 1 ml cell culture medium was added to cover the top agar layer and changed every 3 days for 2 weeks. Colonies were counted, and 20 ng protein was used in each 50-μl reaction mixture containing 32P-TS primer end-labeled with [γ-32P] ATP, TRAP primer mix, dNTP mix, 1× TRAP reaction buffer, and Taq polymerase (Promega Corporation, Madison, WI). To add telomeric repeats to the 3’end of substrate oligonucleotides, the reaction mixture was incubated at 30°C for 30 min in a thermocycler. The telomerase products were amplified by PCR (27 cycles of 94°C for 30 sec and 55°C for 30 sec) and separated by electrophoresis in a 12% non-denaturing polyacrylamide gel. The gel was dried and autoradiographed. For positive and negative controls, we used protein extracts from the telomerase-positive cells supplied in the kit and heat-inactivated (85°C for 10 min) positive cell extract, respectively.

**Statistical analysis**

Student’s t-test for one-way analysis of variance was used to assess differences between untreated control and auranofin-treated groups. P < 0.05 was considered significant.

**Acknowledgements**

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2011-0009165).

**REFERENCES**

1. Komeda, S. and Casini, A. (2012) Next-generation anticancer metallo drugs. Curr. Top. Med. Chem. 12, 219-235.

2. Ott, I. and Gust, R. (2007) Non platinum metal complexes as anti-cancer drugs. Arch. Pharm. Chem. Life Sci. 340, 117-126.

3. Berg, G., Allander, E., Lund, B., Berg, E., Brodin, U., Pettersson, H. and Tran, L. (1988) Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind placebo controlled study. J. Rheumatol. 15, 1747-1754.

4. Kean, W. F. and Kean, I. R. (2008) Clinical pharmacology of gold. Inflammopharmacology 16, 112-125.

5. Jeon, K. I., Byun, M. S. and Jue, D. M. (2003) Gold compound auranofin inhibits IkappaB kinase (IKK) by modifying Cys-179 of IKKbeta subunit. Exp. Mol. Med. 35, 61-66.

6. Angelucci, F., Sayed, A. A., Williams, D. L., Boumis, G., Brunori, M., Dimastrogiovanni, D., Miele, A. E., Pauly, F. and Bellelli, A. (2009) Inhibition of Schistosoma mansoni thiodoecin-glutathione reductase by auranofin: structural and kinetic aspects. J. Biol. Chem. 284, 28977-28985.

7. Grover, S., Asrout, L. D., Williams, C. H. Jr., Schirmer, R. H. and Becker, K. (1998) Human placenta thiodoecin reductase. Isolation of the selencenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J. Biol. Chem. 273, 20096-20101.

8. Mustacich, D. and Powis, G. (2000) Thiodoecin reductase. Biochem. J. 346(PT 1), 1-8.

9. Biaglow, J. E. and Miller, R. A. (2005) The thiodoecin reductase/thiodoecin system: novel redox targets for cancer therapy. Cancer Biol. Ther. 4, 6-13.

10. Powis, G. and Kirkpatrick, D. L. (2007) Thiodoecin signaling as a target for cancer therapy. Curr. Opin. Pharmacol. 7, 392-397.

11. Urg, S. and Becker, K. (2006) On the potential of thio-
redoxin reductase inhibitors for cancer therapy. Semin. Cancer Biol. 16, 452-465.
12. Rigobello, M. P., Scutari, G., Folda, A. and Bindoli, A. (2004) Mitochondrial thioredoxin reductase inhibition by gold(I) compounds and concurrent stimulation of permeability transition and release of cytochrome c. Biochem. Pharmacol. 67, 689-696.
13. Gandin, V., Fernandes, A. P., Rigobello, M. P., Dani, B., Sorrentino, F., Tisato, F., Bjornstedt, M., Bindoli, A., Sturaro, A., Rella, R. and Marzano, C. (2010) Cancer cell death induced by phosphine gold(I) compounds targeting thioredoxin reductase. Biochem. Pharmacol. 79, 90-101.
14. Kim, I. S., Jin, J. Y., Lee, I. H. and Park, S. J. (2004) Auranofin induces apoptosis and when combined with retinoic acid enhances differentiation of acute promyelocytic leukaemia cells in vitro. Br. J. Pharmacol. 142, 749-755.
15. Park, S. J. and Kim, I. S. (2005) The role of p38 MAPK activation in auranofin-induced apoptosis of human promyelocytic leukaemia HL-60 cells. Br. J. Pharmacol. 146, 506-513.
16. Marzano, C., Gandin, V., Folda, A., Scutari, G., Bindoli, A. and Rigobello, M. P. (2007) Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic. Biol. Med. 42, 872-881.
17. Tiekink, E. R. (2008) Anti-cancer potential of gold complexes. Inflammopharmacology 16, 138-142.
18. Nobili, S., Mini, E., Landini, I., Gabbiani, C., Casini, A. and Messari, L. (2010) Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. Med. Res. Rev. 30, 550-580.
19. Hirano, T., Ishihara, K. and Hibi, M. (2000) Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 19, 2548-2556.
20. Chen, Z. and Han, Z. C. (2008) STAT3: a critical transcription activator in angiogenesis. Med. Res. Rev. 28, 185-200.
21. Garcia, R., Bowman, T. L., Niu, G., Yu, H., Minton, S., Muro-Cacho, C. A., Cox, C. E., Falcone, R., Fairclough, R., Parsons, S., Laudano, A., Gazit, A., Levitzki, A., Krakr, A. and Jove, R. (2001) Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20, 2499-2513.
22. Su, F., Ren, F., Rong, Y., Wang, Y., Geng, Y., Feng, M., Ju, Y., Li, Y., Zhao, Z. J., Meng, K. and Chang, Z. (2012) Protein tyrosine phosphatase Meg2 dephosphorylates signal transducer and activator of transcription 3 and suppresses tumor growth in breast cancer. Breast Cancer Res. 14, R38.
23. Konnikova, L., Simeone, M. C., Kruger, M. M., Kotecki, M. and Cochran, B. H. (2005) Signal transducer and activator of transcription 3 (STAT3) regulates human telomerase reverse transcriptase (hTERT) expression in human cancer and primary cells. Cancer Res. 65, 6516-6520.
24. Lavecchia, A., Di Giovanni, C. and Novellino, E. (2011) STAT-3 inhibitors: state of the art and new horizons for cancer treatment. Curr. Med. Chem. 18, 2359-2375.
25. Kim, N. H., Lee, M. Y., Park, S. J., Choi, J. S., Oh, M. K. and Kim, I. S. (2007) Auranofin blocks interleukin-6 signaling by inhibiting phosphorylation of JAK1 and STAT3. Immunology 122, 607-614.
26. Nakaya, A., Sagawa, M., Muto, A., Uchida, H., Ikeda, Y. and Kizaki, M. (2011) The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-kappaB activity. Leuk. Res. 35, 243-249.
27. Dixit, D., Sharma, V., Ghosh, S., Koul, N., Mishra, P. K. and Sen, E. (2009) Manumycin inhibits STAT3, telomerase activity, and growth of glioma cells by elevating intracellular reactive oxygen species generation. Free Radic. Biol. Med. 47, 364-374.
28. Watson, W. H., Heilman, J. M., Hughes, L. L. and Spielberger, J. C. (2008) Thioredoxin reductase-1 knock down does not result in thioredoxin-1 oxidation. Biochem. Biophys. Res. Commun. 368, 832-836.